Witter F R, Rocco L E, Johnson T R
Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Am J Obstet Gynecol. 1992 Mar;166(3):830-4. doi: 10.1016/0002-9378(92)91342-8.
The purpose of this study was to determine if prostaglandin E2 in a controlled-release vaginal pessary can produce cervical ripening at term.
This was a double-blind, randomized, placebo-controlled study conducted at a university center and involving 81 patients with 42 receiving active agent. Categoric data were analyzed by Pearson's chi 2 or logistic regression. Continuous variables were analyzed by analysis of variance and the F test.
Prostaglandin E2 was significantly better than placebo at cervical ripening and at decreasing the time to rupture of membranes, the time to onset of labor, the need to give oxytocin, and the time to vaginal delivery. Multiparous women benefitted more than primiparous ones. The cesarean section rate decreased only for multiparous women. Uterine hyperstimulation occurred only with prostaglandin E2 and after the onset of labor.
Prostaglandin E2, when administered in a controlled-release vaginal pessary, is affective in producing cervical ripening at term. This agent should be used on inpatients who are under continuous monitoring and it should be removed at the onset of labor.
本研究旨在确定控释阴道栓剂中的前列腺素E2在足月时能否促进宫颈成熟。
这是一项在大学中心进行的双盲、随机、安慰剂对照研究,涉及81名患者,其中42名接受活性药物治疗。分类数据采用Pearson卡方检验或逻辑回归分析。连续变量采用方差分析和F检验进行分析。
在促进宫颈成熟、缩短胎膜破裂时间、临产时间、催产素使用需求以及阴道分娩时间方面,前列腺素E2显著优于安慰剂。经产妇比初产妇受益更多。仅经产妇的剖宫产率有所下降。子宫过度刺激仅在使用前列腺素E2时以及临产开始后出现。
控释阴道栓剂给药时,前列腺素E2在足月时能有效促进宫颈成熟。该药物应仅用于持续监测下的住院患者,且在临产开始时应取出。